Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy

Clinical Nephrology

Volumn 67, Issue 3, 2007, Pages 176-181

  Dwyer, J P ^a   Yates, K M ^a   Sumner, E L ^a   Stone, W J ^a,b   Wang, Y ^a   Koury, M J ^a,b   Fogo, A B ^a   Zent, Roy ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic myeloid leukemia; Imatinib mesylate; Membranoproliferative glomerulonephritis; Nephrotic syndrome

Indexed keywords

ALBUMIN; CREATININE; IMATINIB; NITROGEN; UREA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASPIRATION BIOPSY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTRON MICROSCOPY; HEMATOCRIT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; KIDNEY FAILURE; LABORATORY TEST; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEUTROPHIL COUNT; PROTEINURIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; URINARY EXCRETION;

EID: 33947259583     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP67176     Document Type: Article

References (31)

1. Agarwal RG, Gupta KD, Bharadwaj TP. Nephrotic syndrome in the possible terminal blast-cell crisis in myeloid leukemia (a case report). J Assoc Physicians Ind. 1972; 20: 799-801.
2. Bogdanovic R, Kuzmanovic M, Markovic-Lipkovski J, Ognjanovic M, Micic D, Stankovic I, Stajic N, Nikolic V, Bunjevacki G. Glomerular involvement in myelodysplastic syndromes. Pediatr Nephrol. 2001; 16: 1053-1057.
3. Budak-Alpdogan T, Lawrence RA, Bayik M, Akoglu E. Nephrotic syndrome associated with alpha interferon therapy in chronic myeloid leukemia. Clin Nephrol. 1997; 48: 59-60.
4. Chhajlani V, Zingde S, Adwani S, Gothoskar B. Circulating immune complexes in chronic myeloid leukemia: turbidimetric measurement and two-dimensional electrophoretic analysis. Leuk Res. 1983; 7: 565-573.
5. Da'as N, Polliack A, Cohen Y, Amir G, Darmon D, Kleinman Y, Goldfarb AW, Ben-Yehuda D. Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol. 2001; 67: 158-164.
6. Dabbs DJ, Striker LM, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. Am J Med. 1986; 80: 63-70.
7. de Faria JBL, Ribeiro Alves MAVF, Pedrini H, Filho FA. Nephrotic syndrome and membranous glomerulopathy in association with chronic myclogenous leukemia. Rev Ass Med Brasil. 1991; 37: 47-49.
8. Dosa S, Phillips TM, Antonovych TT, Segal A, Guha A, Thompson AM. Acute myelomonocytic leukemia associated with nephrotic syndrome. A case report with immunological studies. Nephron. 1983; 34: 125-129.
9. Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Lydon N, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers C. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kindase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031-1037.
10. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341: 164-172.
11. Feehally J, Hutchinson RM, Mackay EH, Walls J. Recurrent proteinuria in chronic lymphocytic leukemia. Clin Nephrol. 1981; 16: 51-54.
12. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med. 2003; 349: 1451-1463.
13. Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS study. Blood. 2004; 104: A21.
14. Hudkins KL, Gilbertson DG, Carling M, Taneda S, Hughes SD, Holdren MS, Palmer TE, Topouzis S, Haran AC, Feldhaus AL, Alpers CE. Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol. 2004; 15: 286-298.
15. Ishizuka Y, Yokota A, Hara S, Nakaseko C, Matsuura Y, Nishimura M, Saitoh Y. Transient nephrotic syndrome after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Rinsho Ketsueki. 2001; 42: 321-327.
16. Komatsuda A, Miura I, Ohtani H, Hamai K, Wakui H, Imai H, Kobayashi Y, Miura AB, Chubachi A. Crescentic glomerulonephritis accompanied by myelopcroxidase-antineutrophil cytoplasmic antibodies in a patient having myelodysplastic syndrome with trisomy 7. Am J Kidney Dis. 1998; 31: 336-340.
17. Krause DS, van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005; 353: 172-187.
18. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME. Imatinib attenuates diabetic nephropathy in apolipoprotein E knockout mice. J Am Soc Nephrol. 2005; 16: 363-373.
19. Levi I, Dinour D, Ben-Bassat I, Raanani P. Acute myeloid leukemia associated with nephrotic syndrome: case report and literature review. Leuk Lymphoma. 2002; 43: 1133-1136.
20. Morschhauser F, Wittel E, Pagniez D, Lovi V, Rose C, Bauters F, Fenaux P. Glomerular injury in chronic myclomonocytic leukemia. Leuk Lymphoma. 1995; 18: 479-483.
21. O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen J, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian HM, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004.
22. Omura K, Kawamura T, Utsunomiya Y, Abe A, Joh K, Sakai O. Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage-colony-stimulating factor. Am J Kidney Dis. 1996; 27: 883-887.
23. Paydas S, Paydas S, Tuncer I, Zorludemir S, Gonlusen G. A case with membranous glomerulonephritis and myelodysplastic syndrome. Nephron. 1992; 62: 231-232.
24. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia. Nat Rev Cancer. 2005; 5: 172-183.
25. Saitoh T, Murakami H, Uchiumi H, Moridaira K, Maehara T, Matsushima T, Tsukamoto N, Tamura J, Karasawa M, Naruse T, Tsuchiya J. Myelodysplastic syndromes with nephrotic syndrome. Am J Hematol. 1999; 60: 200-204.
26. Saranath D, Advani S, Gangal S. Circulating immune complexes in chronic myeloid leukemia patients at various stages of the disease. Leuk Res. 1983; 7: 771-777.
27. Savikko J, Taskinen E, von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation. 2003; 75: 1147-1153.
28. Sudholt BA, Heironimus JD. Chronic myelogenous leukemia with nephrotic syndrome. Arch Intern Med. 1983; 143: 168-169.
29. Talwar R, Dash SC, Kucheria K. A case of chronic myeloid leukemia complicated with minimal change nephrotic syndrome. Acta Haematol. 2003; 109: 101-103.
30. Theofilopoulos AN. Immune complexes in cancer. N Engl J Med. 1982; 307: 1208-1209.
31. Yoshizaki N, Kohda K, Nakazawa O, Ando M, Miyazaki S, Takahashi M, Muramatsu H, Terada S, Kure T, Niitsu Y. A case of chronic myclogenous leukemia complicated with nephrotic syndrome. Rinsho Ketsueki. 1989; 30: 691-696.